Actively Recruiting

Phase 3
Age: 19Years - 70Years
All Genders
NCT03423680

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression

Led by Korea Otsuka Pharmaceutical Co., Ltd. · Updated on 2024-08-19

390

Participants Needed

1

Research Sites

405 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or inpatients) with type I or II bipolar disorder accompanied by major depressive episode, without any psychotropic features. This study involves patients who are considered by the investigator not to have a proper improvement, despite receiving a mood stabilizer (lithium or valproic acid) for a sufficient (≥ 28 days) period of time during the current depressive episode.

CONDITIONS

Official Title

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression

Who Can Participate

Age: 19Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 69 and < 70 years at the time of informed consent
  • Patients who are able to understand information required for providing a consent
  • Patients who have received a mood stabilizer (lithium or valproic acid)
  • Patients with bipolar I or II disorder accompanied by major depressive episode
  • Montgomery-�c5sberg Depression Rating Scale (MADRS) total score 69 20 at both the screening and baseline visits
Not Eligible

You will not qualify if you...

  • Patients diagnosed with bipolar I or II disorder with mania, mixed or psychotropic features
  • Patients considered to have a high risk of suicide during the study period by the investigator based on current psychotic symptom and the patient's past medical history

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Seounl National University Hospital

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

H

Hoyoung Lee

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression | DecenTrialz